SETDB1 and lung cancer: In contrast, low SETDB1 expression in melanoma (SKCM) and non‐small cell lung cancer (NSCLC) patients was associated with better radiotherapy outcomes, greater immune cell infiltration, and enhanced IFN response following SETDB1 depletion.39